Ocular Pharmacokinetics, Safety and Efficacy of Intracameral Moxifloxacin 0.5% Solution in a Rabbit Model

REFERENCES

• Taban M, Behrens A, Newcomb RL, Nobe MY, Saedi G, Sweet PM, et al. Acute endophthalmitis following cataract surgery: a systematic review of the literature. Arch Ophthalmol 2005;123:613–620
   PubMed Web of Science ®Google Scholar
• Kernt M, Neubauer AS, Liegl RG, Lackerbauer CA, Eibl KH, Alge CS, et al. Intracameral moxifloxacin: in vitro safety on human ocular cells. Cornea 2009;28:553–561
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology 2002;109:13–24
   PubMed Web of Science ®Google Scholar
• Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg 2007;33: 978–988
   Google Scholar
• Masket S. Preventing, diagnosing, and treating endophthalmitis. J Cataract Refract Surg 1998;24:725–726
   PubMed Web of Science ®Google Scholar
• Axer-Siegel R, Stiebel-Kalish H, Rosenblatt I, Strassmann E, Yassur Y, Weinberger D. Cystoid macular edema after cataract surgery with intraocular vancomycin. Ophthalmology 1999;106:1660–1664
   PubMed Web of Science ®Google Scholar
• Villada JR, Vicente U, Javaloy J, Alió JL. Severe anaphylactic reaction after intracameral antibiotic administration during cataract surgery. J Cataract Refract Surg 2005;31:620–621
   PubMed Web of Science ®Google Scholar
• Filip M, Dragne C, Filip A, Măgureanu M, Zemba M, Asandi R. Toxic anterior segment syndrome. Oftalmologia 2006;50:27–29
   PubMedGoogle Scholar
• O’Brien TP, Arshinoff SA, Mah FS. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. J Cataract Refract Surg 2007;33:1790–1800
   PubMed Web of Science ®Google Scholar
• Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol 2005;140:497–504
   PubMed Web of Science ®Google Scholar
• Lane SS, Osher RH, Masket S, Belani S. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. J Cataract Refract Surg 2008;34:1451–1459
   PubMed Web of Science ®Google Scholar
• Espiritu CR, Caparas VL, Boliano JG. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg 2007;33:63–68
   PubMed Web of Science ®Google Scholar
• Güngör SG, Akova YA, Bozkurt A, Yasar U, Babaoglu MO, Cetinkaya A, et al. Aqueous humour penetration of moxifloxocin and gatifloxacin eye drops in different dosing regimens before phacoemulsification surgery. Br J Ophthalmol 2010;95:1272–1275
   PubMed Web of Science ®Google Scholar
• Yağci R, Oflu Y, Dinçel A, Kaya E, Yağci S, Bayar B, et al. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Eye (Lond) 2007;21:990–994
   PubMed Web of Science ®Google Scholar
• Gabrielsson J, Weiner D. Non-compartmental analysis. Methods Mol Biol 2012;929:377–389
   PubMedGoogle Scholar
• Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003;136:500–505
   PubMed Web of Science ®Google Scholar
• Metzler K, Hansen GM, Hedlin P, Harding E, Drlica K, Blondeau JM. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 2004;24:161–167
   PubMed Web of Science ®Google Scholar
• Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:433–438
   PubMed Web of Science ®Google Scholar
• Leaming DV. Practice styles and preferences of U.S. ASCRS members – 2005 survey. ASCRS Symposium on Cataract, IOL and Refractive Surgery; March 2006; San Francisco, California, USA
   Google Scholar
• Montan PG, Wejde G, Setterquist H, Rylander M, Zetterström C. Prophylactic intracameral cefuroxime: evaluation of safety and kinetics in cataract surgery. J Cataract Refract Surg 2002;28:982–987
   PubMed Web of Science ®Google Scholar
• Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996;122:1–17
   PubMed Web of Science ®Google Scholar
• Kowalski RP, Pandya AN, Karenchak LM, Romanowski EG, Husted RC, Ritterband DC, et al. An in vitro resistance study of levofloxacin, ciprofloxacin and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. Ophthalmology 2001;108:1826–1829
   PubMed Web of Science ®Google Scholar
• Benz MS, Scott IU, Flynn Jr HW, Unonius N, Miller D. Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. Am J Ophthalmol 2004;137:38–42
   PubMed Web of Science ®Google Scholar
• Murphy CC, Nicholson S, Quah SA, Batterbury M, Neal T, Kaye SB. Pharmacokinetics of vancomycin following intracameral bolus injection in patients undergoing phacoemulsification cataract surgery. Br J Ophthalmol 2007;91:1350–1353
   PubMed Web of Science ®Google Scholar
• Bergogne-Bérézin E. Clinical role of protein binding of quinolones. Clin Pharmacokinet 2002;41:741–750
   PubMed Web of Science ®Google Scholar
• Oh C, Saville BA, Cheng YL, Rootman DS. A compartment model for the ocular pharmacokinetics of cyclosporine in rabbits. Pharm Res 1995;12:433–437
   PubMed Web of Science ®Google Scholar
• Becker B, Constant MA. Species variation in facility of aqueous outflow. Am J Ophthalmol 1956;42:189–194
   PubMed Web of Science ®Google Scholar
• Schoenwald RD. Ocular pharmacokinetics. Textbook of ocular pharmacology. 3rd ed. Philadelphia: Lipincott-Raven; 1997
   Google Scholar
• Kim DH, Stark WJ, O’Brien TP, Dick JD. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology 2005;112:1992–1996
   PubMed Web of Science ®Google Scholar
• Schentag JJ. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae. J Chemother 2002;14:13–21
   PubMedGoogle Scholar
• Kim SY, Park YH, Lee YC. Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells. Clin Experiment Ophthalmol 2008;36:367–370
   PubMed Web of Science ®Google Scholar
• Arbisser LB. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery. J Cataract Refract Surg 2008;3:1114–1120
   Google Scholar
• Arshinoff SA. Advantages and use of intracameral moxifloxacin for bacterial prophylaxis in cataract surgery. ASCRS Symposium on Cataract, IOL and Refractive Surgery; April 2007; San Diego, CA, USA
   Google Scholar